Insulin Prices: House Hearing Displays Bipartisan Commitment To Rapid Reform
Executive Summary
Reform "is going to happen,” promised Energy & Commerce Oversight Subcommittee Chair Diana DeGette, suggesting the panel’s next hearing on insulin price reform may be held in July.
You may also be interested in...
Glumetza Patent Settlement Without An Authorized Generic Plus Price Hike Spawns Litigation
Walgreen and other retailers allege no-authorized generic patent settlement for extended-release metformin allowed Santarus (Valeant) to block generic entry for four years while raising the price more than 750%.
Insulin List Prices Would Be Lowered To 2006 Levels Under House Bill
Rebates would be prohibited and insurance coverage required without restrictions for insulin products with steep price roll-backs under bill from Reps. Diana DeGette, D-CO, and Tom Reed, R-NY.
Lilly Has A Couple Of Controversies To Cover During Earnings Call
Q1 Earnings Preview: From troubling safety data for tanezumab to pressure on insulin prices, Lilly is likely to face questions about controversies in its R&D pipeline and commercial portfolio during its first quarter earnings call on April 30.